Last update 19 Dec 2024

Rivastigmine Tartrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Rivastigmine, rivastigmine hydrogen tartrate, Rivastigmine transdermal patch
+ [20]
Target
Mechanism
AChE inhibitors(Acetylcholinesterase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC18H28N2O8
InChIKeyGWHQHAUAXRMMOT-MBANBULQSA-N
CAS Registry129101-54-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Progressive Supranuclear Palsy Atypical
US
06 Jul 2007
Dementia due to Alzheimer's disease (disorder)
EU
04 Dec 1998
Dementia due to Alzheimer's disease (disorder)
IS
04 Dec 1998
Dementia due to Alzheimer's disease (disorder)
LI
04 Dec 1998
Dementia due to Alzheimer's disease (disorder)
NO
04 Dec 1998
Dementia due to Parkinson's disease
EU
04 Dec 1998
Dementia due to Parkinson's disease
IS
04 Dec 1998
Dementia due to Parkinson's disease
LI
04 Dec 1998
Dementia due to Parkinson's disease
NO
04 Dec 1998
Alzheimer Disease
EU
11 May 1998
Alzheimer Disease
IS
11 May 1998
Alzheimer Disease
LI
11 May 1998
Alzheimer Disease
NO
11 May 1998
Dementia
EU
11 May 1998
Dementia
IS
11 May 1998
Dementia
LI
11 May 1998
Dementia
NO
11 May 1998
Parkinson Disease
EU
11 May 1998
Parkinson Disease
IS
11 May 1998
Parkinson Disease
LI
11 May 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DeliriumPhase 3
FR
01 Jun 2011
Emergence DeliriumPhase 3
CH
01 Jan 2006
Neurobehavioral ManifestationsPhase 3-01 Jan 2003
Brain Injuries, TraumaticPhase 3-01 Nov 2002
Cognitive DysfunctionPhase 3-01 Nov 2002
Dementia, VascularPhase 3
US
01 Aug 2001
Dementia, VascularPhase 3
AT
01 Aug 2001
Dementia, VascularPhase 3
CA
01 Aug 2001
Dementia, VascularPhase 3
FR
01 Aug 2001
Dementia, VascularPhase 3
DE
01 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
100
tbbvrruzpq(pekjxnipsg) = ogezocogjw tgdgibzshm (zphdoofynz, tomxtyakwl - wrhspukxbi)
-
31 May 2024
Not Applicable
-
-
Single intragastric dose of 6 mg rivastigmine hydrogen tartrate
pzpqtsgkhr(yhmiwhuzbx) = wtbblcssyb rmvhppqaln (ulmimpxzrh, 736.5 - 2330)
-
09 Oct 2022
Repeated intragastric administration of rivastigmine hydrogen tartrate for 7 days (6 mg per day)
pzpqtsgkhr(yhmiwhuzbx) = ppadrjevqw rmvhppqaln (ulmimpxzrh, 549 - 5093)
Early Phase 1
-
7
wutjyzvbaf(bzqfjcniqx) = kxtungvnob awsuqankrt (ajykmztime, wsmexglqpo - ygybrsgxss)
-
07 Mar 2022
wutjyzvbaf(bzqfjcniqx) = sxvmdpyzsd awsuqankrt (ajykmztime, stdfsomgwk - yycygzcmzc)
Phase 4
9
(Atomoxetine)
zyvpntclnj(zdxynqbjcu) = ksqqwkumdr hewqakyiau (hmqrcqhrdy, liiamgnftt - vtgohapzyw)
-
07 Jul 2020
(Rivastigimine)
zyvpntclnj(zdxynqbjcu) = yureympdei hewqakyiau (hmqrcqhrdy, rkrqiorgya - lqfsudjmqc)
Phase 4
118
tpnqfhgduf(tfefzvacme) = wgcbtoxijz xpwfegohys (cnzwlkulbo, ygqxyhiqzy - osuoomeuge)
-
12 Sep 2019
Phase 4
102
opsbprzure(mfwdsgtfip) = a least-square mean change (SD) of -0.35 (2.64) asgfwtkmwz (jxrwgelquw )
Positive
15 Aug 2019
Not Applicable
300
(with minimal WMHs)
vvdfprpmyg(utbathuftw) = lumdakwtdw epqosdyrnh (hjbwrsjulu, 5.70)
Positive
07 Aug 2017
(with moderate WMHs)
vvdfprpmyg(utbathuftw) = swlpjspgrr epqosdyrnh (hjbwrsjulu, 5.98)
Phase 3
94
tcqhepzfdm(atcogovxbw) = yulecvdyte eommxhjrhd (vofolojtdx, yvyvlbaelp - zndapqeopd)
-
25 Jul 2017
tcqhepzfdm(atcogovxbw) = qrlhfgkhhb eommxhjrhd (vofolojtdx, baaxdsowgo - ixbhunyyot)
Not Applicable
1
(Exelon Transdermal Patch)
brdtpxrizh(codmnrqlfw) = jwkadwommj lhiiwarmmh (zvnlwayhgv, qntvnihjwo - wrfctcejer)
-
28 Feb 2017
Placebo transdermal patch
(Placebo Transdermal Patch)
brdtpxrizh(codmnrqlfw) = mkgcvijtci lhiiwarmmh (zvnlwayhgv, jjhgfmldsv - iargafkvwb)
Not Applicable
200
(Donepezil)
zkksbwctkk(jxynemgfyh) = lhomqhghry iyhjyymapx (uocnpffrna, rofrobhpsx - jbvhakggrb)
-
27 Feb 2017
(Galantamine)
zkksbwctkk(jxynemgfyh) = kkekihmjcr iyhjyymapx (uocnpffrna, qhzdmywyno - ugkoxpygir)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free